Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.85 −0.7% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.99 +10.5% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.40 −0.5% SGZ 0.045 +0.0% S 0.155 +29.2% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0%
Financings Routine −

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Financing Finalized at Discount as Dilution Concerns Weigh on Stock

By The Northwire Desk — AI Analysis May 19, 2026 · 07:00 MDNA · 0.54 MEDICENNA THERAPEUTICS CORP. J
Executive Summary
  • Medicenna Therapeutics has finalized terms for a public offering of units priced at $0.50 per unit.
  • Each unit consists of one common share and one-half warrant with an exercise price of $0.65 expiring in three years.
  • The offering is underwritten by Bloom Burton Securities Inc., expected to close around May 27, 2026.
  • Proceeds are designated for clinical/regulatory development of MDNA11 and MDNA113, working capital, and general corporate purposes.
  • This follows the launch announcement on May 13, 2026, which was priced as a best-efforts marketed offering.
Material Impact
  • The financing is dilutive to existing shareholders given the $0.50 offering price against recent trading levels near $0.60-$0.66 prior to finalization.
  • While essential for extending cash runway beyond Q3 2026, the discount pricing signals market pressure and lack of premium valuation support.
  • The terms are consistent with previous announcements (May 13), making this a follow-up event rather than new information.
  • Dilution risk is immediate upon closing, likely suppressing stock price momentum despite clinical progress.
MDNA · Price
Company Overview
  • Medicenna Therapeutics develops immunotherapy assets focused on IL-2 Superkines and bifunctional proteins.
  • Flagship asset MDNA11 is a long-acting "beta-enhanced not-alpha" IL-2 Superkine currently in Phase 1/2 ABILITY-1 trial for advanced solid tumors.
  • MDNA113 is a first-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional protein advancing toward IND submission.
  • Bizaxofusp (MDNA55) targets recurrent glioblastoma with Phase 2b data showing improved overall survival compared to standard care.
Read the original news release →

More from MEDICENNA THERAPEUTICS CORP. J

Jun 26, 2026 · 08:45

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Earnings Jun 11, 2026 · 07:00

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

M&A / Property Jun 03, 2026 · 07:00

ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion

Other May 28, 2026 · 09:10

Medicenna Secures $12.4M Lifeline Amidst Dilution Concerns and Clinical Milestones

Financings May 22, 2026 · 07:00

Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals

Financings May 13, 2026 · 16:01

Cash Runway Expiry Triggers Dilutive Financing Despite Clinical Milestones

Financings